Kevin Thornal - Hologic Group Solutions
| HO1 Stock | EUR 69.00 0.50 0.73% |
Insider
Kevin Thornal is Group Solutions of Hologic
| Age | 49 |
| Phone | 508 263 2900 |
| Web | https://www.hologic.com |
Kevin Thornal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kevin Thornal against Hologic stock is an integral part of due diligence when investing in Hologic. Kevin Thornal insider activity provides valuable insight into whether Hologic is net buyers or sellers over its current business cycle. Note, Hologic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Hologic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kevin Thornal over two months ago Disposition of 6063 shares by Kevin Thornal of Nevro Corp at 4.85 subject to Rule 16b-3 |
Hologic Management Efficiency
The company has return on total asset (ROA) of 0.0858 % which means that it generated a profit of $0.0858 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.206 %, meaning that it generated $0.206 on every $100 dollars invested by stockholders. Hologic's management efficiency ratios could be used to measure how well Hologic manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rene Faber | Sartorius Stedim Biotech | 43 | |
| Vered Keisar | Resmed Inc DRC | N/A | |
| Heiko Imhl | Sartorius Stedim Biotech | N/A | |
| AM AM | Resmed Inc DRC | 80 | |
| Amy Wakeham | Resmed Inc DRC | N/A | |
| Jamie Samath | Intuitive Surgical | 52 | |
| Pascale Boissel | Sartorius Stedim Biotech | N/A | |
| Mei Wang | Sartorius Aktiengesellschaft | N/A | |
| David Pendarvis | ResMed Inc | 64 | |
| Constance Bienfait | ResMed Inc | N/A | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Philip Kim | Intuitive Surgical | N/A | |
| Amelie Buton | Sartorius Stedim Biotech | 32 | |
| John Mackay | Sartorius Stedim Biotech | 61 | |
| Urvashi Tyagi | ResMed Inc | N/A | |
| Rainer Lehmann | Sartorius Aktiengesellschaft | 48 | |
| Urvashi Tyagi | Resmed Inc DRC | N/A | |
| Manfred Werner | Sartorius Aktiengesellschaft | N/A | |
| Gary Guthart | Intuitive Surgical | 57 | |
| Patricia Spannagel | Sartorius Aktiengesellschaft | N/A | |
| Kaushik Ghoshal | Resmed Inc DRC | 55 | |
Management Performance
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0858 |
Hologic Leadership Team
Elected by the shareholders, the Hologic's board of directors comprises two types of representatives: Hologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hologic. The board's role is to monitor Hologic's management team and ensure that shareholders' interests are well served. Hologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Malenchini, Chief Officer | ||
| Mike Kelly, Chief Affairs | ||
| Stephen MacMillan, CEO Chairman | ||
| Jan Verstreken, Group International | ||
| Kevin Thornal, Group Solutions | ||
| Ryan Simon, VP Relations | ||
| Karleen Oberton, Chief Officer | ||
| Monica Berthelot, VP Staff | ||
| Elisabeth Hellmann, Sr Communications | ||
| John Griffin, G Counsel |
Hologic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0858 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 18.25 B | |||
| Shares Outstanding | 246.55 M | |||
| Shares Owned By Insiders | 0.73 % | |||
| Shares Owned By Institutions | 99.99 % | |||
| Price To Book | 3.70 X | |||
| Price To Sales | 3.52 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Hologic Stock
When determining whether Hologic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hologic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hologic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hologic Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hologic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Hologic Stock please use our How to Invest in Hologic guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.